Risk of volume depletion events with concomitant use of sodium glucose co‐transporter 2 inhibitors and loop diuretics: A self‐controlled case series study-Reference-Cited by-同舟云学术

Risk of volume depletion events with concomitant use of sodium glucose co‐transporter 2 inhibitors and loop diuretics: A self‐controlled case series study

Published:2022-07 Issue:10 Volume:31 Page:1102-1109
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Lewellyan Colleen M.¹,Spoutz Patrick²,Schaefer Monica³,Patterson Mark E.⁴^ORCID

Affiliation:

1. Kansas City VA Medical Center Kansas City Missouri USA

2. Department of Veterans Affairs VISN #20 VA Northwest Health Network Vancouver Washington USA

3. Department of Veterans Affairs VISN #15 VA Heartland Network Kansas City Missouri USA

4. University of Missouri‐Kansas City School of Pharmacy Kansas City Missouri USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5496

Reference26 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

3. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

4. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

5. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

2. Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis;European Heart Journal;2023-08-22